Circulating secreted frizzled-related protein 5 and chronic kidney disease in patients with acute ST-segment elevation myocardial infarction. (October 2018)

• Record Type: Journal Article
• Authors: Wang, Chao-Ping; Yu, Teng-Hung; Wu, Cheng-Ching; Hung, Wei-Chin; Hsu, Chia-Chang; Tsai, I-Ting; Tang, Wei-Hua; Chung, Fu-Mei; Houng, Jer-Yiing; Lee, Yau-Jiunn; Lu, Yung-Chuan
• Is Part Of: Cytokine. Volume 110(2018)
• Page Start: 367
• Page End: 373
• Publication Date: 2018-10
• Subjects: Chronic kidney disease -- Glomerular filtration rate -- Secreted frizzled-related protein-5 -- ST-segment elevation myocardial infarction; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2018.04.009
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: We evaluate patients with acute STEMI who did or did not have CKD. We examine whether plasma Sfrp5 levels were altered in patients with CKD. With increasing Sfrp5, the patients had higher frequency of stage 4 or 5 CKD. Plasma Sfrp5 level was associated with CKD for patients >65 years old. Sfrp5 may play a role in the pathogenesis of CKD in older acute STEMI patients. Abstract: Secreted frizzled-related protein-5 (Sfrp5) known as secreted antagonist binds to Wnt protein. It has been shown to be downregulated by histone acetylation and promoter methylation, and to function as a tumor suppressor gene by inducing apoptosis in renal cell cancer cells. However, its relationship with chronic kidney disease (CKD) has not been well studied. Our objective was to investigate the effect of plasma Sfrp5 levels in subjects with and without CKD. Plasma Sfrp5 levels were determined by enzyme-linked immunosorbent assays in 196 consecutive patients with acute ST-segment elevation myocardial infarction (STEMI). CKD was defined as an estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m 2 . For the purpose of this study, stage 1 or 2 CKD patients (eGFR ≥ 60 ml/min per 1.73 m 2 ) were classified as not having CKD. With increasing Sfrp5 tertiles, the patients had higher frequencies of hypertension, stage 4 or 5 CKD, and waist-to-hip ratio, incrementally lower eGFRs and serum hemoglobin levels, and higher levels of blood urine nitrogen (BUN), creatinine, and adiponectin. Multivariate logistic regression analysis showed that an increased plasma Sfrp5 level was independently associated with CKD for all subjects (adjusted odds ratio (OR), 1.08; 95% confidence interval (CI), 1.02–1.14; p = 0.011). Sfrp5 was also significantly positively related to BUN, creatinine, and adiponectin, and significantly negatively related to eGFR and hemoglobin. When the patients were stratified by age, plasma Sfrp5 level was independently related to CKD for patients >65 years old (adjusted OR, 1.10; 95% CI, 1.00–1.20; p = 0.045), however, the association was not significant for those <65 years old. In addition, Sfrp5 was significantly positively related to BUN, creatinine, and adiponectin, and significantly negatively related to eGFR and hemoglobin in patients >65 years old. Our results suggest that Sfrp5 may play a role in the pathogenesis of CKD in acute STEMI patients who are older than 65 years.